Real-World Evidence Library

Full citation

Trapani D, Douillard JY, Winer EP, et al. The global landscape of treatment standards for breast cancer. J Natl Cancer Inst. 2021;113:1143-1155.

Full citation

Tolaney SM, Punie K, Carey LA, et al. Real-world treatment patterns and outcomes in patients with HR+/HER2-metastatic breast cancer treated with chemotherapy in the United States. ESMO Open. 2024;9:103691.

Full citation

Tarantino P, Foldi J, et al. Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (MBC)—retrospective study from the nationwide Flatiron database. Clin Cancer Res. 2025;31(12 suppl):P1-08-08.

No publication URL was provided in the source PDF.

Full citation

Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis— focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378.

Full citation

Shnayder-Adams MM, Sekhar A. Micro-habits for life-long learning. Abdom Radiol (NY). 2021;46:5509-5512.

Full citation

Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423-1433.

Full citation

Rugo HS, Bardia A, Gradishar WJ, et al. Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. Breast. 2025;82:104485.

Full citation

Qin Q. Advances in research and current challenges in the treatment of advanced HER2-low breast cancer. Front Cell Dev Biol. 2025;13:1451471.

Full citation

Nozawa K, Iwata H, Mukohara T, et al. Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study. ESMO Open. 2025;10:105511.

Full citation

Nezirevic S, Anders C, Dent S, et al. Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer. Breast Cancer Res Treat. 2025;214:329-337.

Full citation

Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609.

Full citation

Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20.

Full citation

Modi S, Jacot W, Iwata H, et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025;31:4205-4213.

Full citation

Modi S, Byng D, Zhang S, et al. Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States. Breast. 2026;86:104721.

Full citation

Mathiot L, Kerdraon O, Le Borgne F, et al. Real-world analysis of HER2-ultralow in HR+/HER2-metastatic breast cancer: prevalence and first-line chemotherapy outcomes. Ther Adv Med Oncol. 2025;17:17588359251378863.

Full citation

Loibl S, Park YH, Shao Z, et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 394(9):845-857.

Full citation

Loibl S, Loirat D, Tolaney SM, et al. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer. 2023;178:23-33.

Full citation

Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610-2619.

Full citation

LeVee A, Deutsh A, Lindgren ES, et al. New drugs, new toxicities: side effects of new and emerging breast cancer therapies. Am Soc Clin Oncol Educ Book. 2025;45:e473384.

Full citation

Kang S, Kim SB. Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer. Ther Adv Med Oncol. 2025;17:17588359251324889.

Full citation

Jourdain H, Di Meglio A, Mansouri I, Desplas D, Zureik M, Haddy N. Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study. ESMO Open. 2024;9:104083.

Full citation

Huang J, Chen L, Song L, et al. Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China. Front Oncol. 2025;15:1527990.

Full citation

Gehlert S, Hudson D, Sacks T. A critical theoretical approach to cancer disparities: breast cancer and the social determinants of health. Front Public Health. 2021;9:674736.

Full citation

Denduluri N, Espirito JL, Hackshaw MD, Wentworth C, Recchia T, Kwong WJ. Retrospective observational study of outcomes in HER2-positive metastatic breast cancer (mBC) patients treated with ado-trastuzumab emtansine (T-DM1) and subsequent treatments after T-DM1 in the United States. Drugs Real World Outcomes. 2023;10:177-186.

Full citation

Cortes J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025;393:1912-1925.

Full citation

Ciruelos E, Garcia-Saenz JA, Gavila J, Martin M, Rodriguez CA, Rodriguez-Lescure A. Safety profile of trastuzumab deruxtecan in advanced breast cancer: expert opinion on adverse event management. Clin Transl Oncol. 2024;26:1539-1548.

Full citation

Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021;11:808.

Full citation

Bourdeanu L, Luu T, Baker N, et al. Barriers to treatment in patients with locally advanced breast cancer. J Natl Compr Canc Netw. 2013;11:1193-1198.

Full citation

Botticelli A, Caputo R, Scagnoli S, et al. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study. Oncologist. 2024;29:303-310.

Full citation

Bardia A, Rugo HS, Tolaney SM, et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 2024;42:1738-1744.

Full citation

Bardia A, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025;43:285-296.

Full citation

Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110-2122.

Full citation

Association of Community Cancer Centers. Multidisciplinary breast cancer resources. ACCC website. Accessed September 5, 2026. Available at: https://www.accc-cancer.org/education-and-resources/cancer-types/breast-cancer/multidisciplinary-breast-cancer-resources

Full citation

Anders C, Neuberger E, Schwartz NRM, et al. Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases. Int J Clin Oncol. 2025;30:1982-1991.

No publication URL was provided in the source PDF.

Full citation

Anders C, Neuberger E, Bartley K, et al. Real-world clinical outcomes in patients with HER2+ metastatic breast cancer receiving tucatinib-based therapy after 2 or more prior metastatic HER2-directed regimens. Cancer Control. 2025;32:10732748251327711.